UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006521
Receipt number R000007732
Scientific Title Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease
Date of disclosure of the study information 2011/10/11
Last modified on 2020/10/19 19:52:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease

Acronym

Switch trial from IR to ER of Pramipexole

Scientific Title

Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease

Scientific Title:Acronym

Switch trial from IR to ER of Pramipexole

Region

Japan


Condition

Condition

Parkinson's disease

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess if Parkinson's disease patients can benefit of nocturnal and early morning symptoms, preference, and convenience by switching from Pramipexole immediate release (IR) to Pramipexole extended release (ER).

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Preference and convenience for ER
Nocturnal and early morning symptoms
UPDRS part2 and part3 score

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Rapid switch of Pramipexole ER (once in a day) which is same dose as IR. The period of administration is 8 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Parkinson's disease patients with nocturnal and early morning symptoms.
Patients doesn't take dopamine agonist except Pramipexole.
Yahr stage is 2-4 at on-phase.

Key exclusion criteria

Patients
take other dopamin agonist
have psychiatric symptoms
have hypotension
have cardiac, renal, and hepatic disease
are pregnant
take the medicine of other clinical trial

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Masashi
Middle name
Last name Takanashi

Organization

Juntendo University School of Medicine

Division name

Department of Neurology

Zip code

113-8421

Address

2-1-1, Bunkyo, Hongo, Tokyo

TEL

03-3813-3111

Email

nassy-m@juntendo.ac.jp


Public contact

Name of contact person

1st name Masashi
Middle name
Last name Takanashi

Organization

Juntendo University

Division name

Department of Neurology

Zip code

113-8421

Address

Department of Neurology

TEL

03-3813-3111

Homepage URL


Email

nassy-m@juntendo.ac.jp


Sponsor or person

Institute

Department of Neurology, Juntendo University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Juntendo Hospital

Address

3-1-3, Hongo, Bunkyo, Tokyo

Tel

03-3813-3111

Email

none


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 10 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2011 Year 09 Month 05 Day

Date of IRB


Anticipated trial start date

2011 Year 10 Month 01 Day

Last follow-up date

2012 Year 12 Month 20 Day

Date of closure to data entry

2012 Year 12 Month 31 Day

Date trial data considered complete

2013 Year 01 Month 31 Day

Date analysis concluded

2013 Year 02 Month 15 Day


Other

Other related information



Management information

Registered date

2011 Year 10 Month 11 Day

Last modified on

2020 Year 10 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007732


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name